Literature DB >> 18636145

VEGF blockade decelerates the growth of a murine experimental osteosarcoma.

Dezhen Yin1, Tanghong Jia, Weiming Gong, Haiying Yu, Paul H Wooley, Michael P Mott, Shang-You Yang.   

Abstract

Retrovirus-mediated sFlt-1 gene modification was performed to examine the influence of VEGF in controlling the growth of an experimental osteosarcoma in mice. Human osteosarcoma G-292 cells were in vitro infected with retroviral vectors encoding soluble Flt-1 or LacZ gene before transplanted into proximal tibiae of immune deficient SCID mice to establish experimental orthotopic osteosarcoma. Daily observation and biweekly microCT were performed to monitor tumor development and progression till sacrifice at 8 weeks after tumor cell inoculation for histological and molecular analyses. Successful transgene expression was confirmed in the culture media of sFlt-1 transduced G-292 cells using ELISA, and with positive X-gal staining of the LacZ transduced cells. Noteworthy tumors were grown in all mice on the tibiae receiving G-292 cell inoculation, with clear detection on microCT images starting 2 weeks after inoculation. Over the time period, tumors derived from sFlt-1 transduced G-292 cells were distinctively smaller in size when compared to the ones from wide-type G-292 and G-292-LacZ cells. Histology showed typical osteosarcoma characteristics including severe cellular pleomorphism, bone erosions, and neo-vascularization. Real-time polymerase chain reaction indicated significantly higher sFlt-1 expression in sFlt-1 transduced groups than the wild-type G-292 or LacZ-treated groups. Strong expression of oncogenes c-myc and c-fos were also obvious, along with the expression of VEGF in the primary tumor tissue. Overall, data suggest that retrovirus-mediated sFLT-1 gene modification decelerates the osteosarcoma tumor growth in this murine model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636145

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.

Authors:  Gang Han; Yan Wang; Wenzhi Bi; Jinpeng Jia; Wei Wang; Meng Xu
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

Review 2.  Stratifying osteosarcoma: minimizing and maximizing therapy.

Authors:  Lisa M Niswander; Su Young Kim
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

3.  Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.

Authors:  John Lammli; Minyan Fan; Howard G Rosenthal; Meghan Patni; Elizabeth Rinehart; Gerardo Vergara; Elizabeth Ablah; Paul H Wooley; George Lucas; Shang-You Yang
Journal:  Int Orthop       Date:  2012-08-02       Impact factor: 3.075

4.  Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.

Authors:  Helen J Knowles; Karl-Ludwig Schaefer; Uta Dirksen; Nicholas A Athanasou
Journal:  BMC Cancer       Date:  2010-07-16       Impact factor: 4.430

5.  Antigen-specific tolerogenic dendritic cells ameliorate the severity of murine collagen-induced arthritis.

Authors:  Bin Ning; Jianlu Wei; Aijun Zhang; Weiming Gong; Jinqiu Fu; Tanghong Jia; Shang-You Yang
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

6.  A case report of apatinib in treating osteosarcoma with pulmonary metastases.

Authors:  Yong Zhou; Wengeng Zhang; Fan Tang; Yi Luo; Li Min; Wenli Zhang; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

7.  Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.

Authors:  Kai Zhao; Shang-You Yang; Jun Geng; Xuan Gong; Weiming Gong; Lin Shen; Bin Ning
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

8.  RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance.

Authors:  Jinfeng Ma; Hai Huang; Zenggang Han; Changzheng Zhu; Bin Yue
Journal:  Biomed Res Int       Date:  2015-07-01       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.